Literature DB >> 3473246

Demographic patterns for mesothelioma in the United States.

R R Connelly, R Spirtas, M H Myers, C L Percy, J F Fraumeni.   

Abstract

Incidence rates for pleural and peritoneal mesotheliomas in about 10% of the U.S. population were examined by various demographic characteristics based on 1973-84 data from the Surveillance, Epidemiology, and End Results Program. Although pleural mesothelioma was more common than peritoneal mesothelioma, both are rare diseases in this country. Pleural mesothelioma incidence rates among white males increased over time and were highest in seaboard areas where shipyards have been located (Seattle, San Francisco-Oakland, Hawaii). The significant secular change was attributed to both period (date of diagnosis) and cohort (date of birth) effects. Pleural mesothelioma incidence rates among white males were nearly 50% higher in the 1980-84 period compared to those in 1975-79; the cohort effect rose to a peak for the 1905-9 birth cohort and then declined. These effects probably reflect changes in asbestos exposure patterns in the past and more recent changes in clinical awareness and coding rules for mesothelioma. Geographic analysis of U.S. death certificates for pleural cancer among white males and females dying during 1968-78 indicated that mortality rates were significantly elevated in several areas that have had asbestos-manufacturing plants or shipyards. Analyses of mortality rates must be viewed with caution, since mesothelioma is considerably underreported on death certificates.

Entities:  

Mesh:

Year:  1987        PMID: 3473246

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  27 in total

1.  The incidence of mesothelioma has not decreased for the last twenty years in Southeast region of Anatolia.

Authors:  A I Carkanat; A Abdurrahman; O Abakay; S Cengizhan; S H Selimoglu; A Senyigit
Journal:  Afr Health Sci       Date:  2011-09       Impact factor: 0.927

2.  Use of death certificates for mesothelioma surveillance.

Authors:  L K Davis; T R Martin; B Kligler
Journal:  Public Health Rep       Date:  1992 Jul-Aug       Impact factor: 2.792

3.  Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man with a constitutional NF2 missense mutation.

Authors:  M E Baser; H Rai; A J Wallace; D G R Evans
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

4.  An updated cohort mortality study of workers at a northeastern United States petroleum refinery.

Authors:  K W Collingwood; G K Raabe; O Wong
Journal:  Int Arch Occup Environ Health       Date:  1996       Impact factor: 3.015

5.  Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma.

Authors:  Prasad S Adusumilli; Mei-Ki Chan; Yun Shin Chun; Michael Hezel; Ting-Chao Chou; Valerie W Rusch; Yuman Fong
Journal:  Cancer Biol Ther       Date:  2006-01-12       Impact factor: 4.742

Review 6.  Malignant mesothelioma: facts, myths, and hypotheses.

Authors:  Michele Carbone; Bevan H Ly; Ronald F Dodson; Ian Pagano; Paul T Morris; Umran A Dogan; Adi F Gazdar; Harvey I Pass; Haining Yang
Journal:  J Cell Physiol       Date:  2012-01       Impact factor: 6.384

7.  Asbestos diseases and compensation.

Authors:  L Arblaster; P Hatton; M S Schweiger; E R Renvoize; D Howel
Journal:  BMJ       Date:  1990-11-10

8.  Dissimilar peptide growth factors can induce normal human mesothelial cell multiplication.

Authors:  M A Laveck; A N Somers; L L Moore; B I Gerwin; J F Lechner
Journal:  In Vitro Cell Dev Biol       Date:  1988-11

9.  Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.

Authors:  D J Sugarbaker; J P Garcia; W G Richards; D H Harpole; E Healy-Baldini; M M DeCamp; S J Mentzer; M J Liptay; G M Strauss; S J Swanson
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

10.  Malignant pleural mesothelioma without asbestos exposure with distant metastasis in a peripheral lymph node: a case report.

Authors:  Surya Kant; Sanjay Kumar Verma
Journal:  Lung India       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.